Chinese Japanese Germany Korea


Description In vitro In vivo
Pomalidomide structure
Chemical Name:
IMiD 3;ActiMid;CC-4047;Pomalidomide;Pomalidomide-d4;Actimid (Celgene);Pomalidomide, >=99%;Pomalidomide(CC-4047);pomalidomide,Pomalyst;Pomalidomide high quality
Molecular Formula:
Formula Weight:
MOL File:

Pomalidomide Properties

Melting point:
318.5 - 320.5°
storage temp. 
DMSO: ≥14mg/mL
  • Risk and Safety Statements
WGK Germany  3
RTECS  NR3397905
HS Code  29251900

Pomalidomide price More Price(8)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich P0018 Pomalidomide ≥98% (HPLC) 19171-19-8 5mg $113 2018-11-13 Buy
Sigma-Aldrich P0018 Pomalidomide ≥98% 19171-19-8 25mg $295 2018-11-13 Buy
TCI Chemical P2074 Pomalidomide >98.0%(HPLC) 19171-19-8 25mg $11 2018-11-22 Buy
TCI Chemical P2074 Pomalidomide >98.0%(HPLC) 19171-19-8 100mg $31 2018-11-22 Buy
Cayman Chemical 19877 Pomalidomide ≥98% 19171-19-8 5mg $55 2018-11-19 Buy

Pomalidomide Chemical Properties,Uses,Production


Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels.
Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls.

In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity.


In February 2013, the US FDA approved pomalidomide (also known as CC4047) for the treatment of multiple myeloma (MM) in patients with disease progression after receiving other cancer therapeutics. Pomalidomide is a 4-amino analog of thalidomide with enhanced potency and an improved toxicity profile. Pomalidomide and thalidomide exert their effects by modulation of immunity, inhibition of angiogenesis, interference with the bone/tumor microenvironment, and inhibition of the cereblon protein. Pomalidomide potently inhibited in vitro proliferation in a variety of human MM cell lines, IC50~10 nM, while thalidomide showed almost no inhibition up to 100 μM. In mouse MM tumor models, 50 mg/kg daily doses of pomalidomide resulted in marked inhibition of tumor growth after 15 days of treatment and complete regression in 3–6 weeks versus thalidomide-treated controls at the same dose. Pomalidomide is prepared by condensation of 4-nitrophthalic anhydride with 3-aminopiperidine-2,6-dione followed by catalytic hydrogenation of the nitro group.

Chemical Properties

Yellow Solid


Celgene Corporation (United States)


Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM


Pomalidomide is a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.


Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.


ChEBI: An aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies.

brand name


Pomalidomide Preparation Products And Raw materials

Raw materials

Preparation Products

Pomalidomide Suppliers

Global( 216)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19918 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21696 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20672 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 661 60
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24191 60
Lianyungang happen teng technology co., LTD
15950718863 CHINA 296 58
Hebei Chisure Biotechnology Co., Ltd.
0311 66567340 CHINA 1017 58
Zhenfei Industrial Co. Ltd.
+86 15318988277 CHINA 75 58

View Lastest Price from Pomalidomide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-08-26 Pomalidomide
US $0.00-0.00 / KG 1g 99.0% 10kg/month Beijing Yibai Biotechnology Co., Ltd
2019-07-05 Pomalidomide high quality
US $10.00 / KG 1KG 99% 10 mt Hebei Guanlang Biotechnology Co., Ltd.
2018-12-19 Pomalidomide
US $1.00 / kg 1kg 95%-99% 100kg career henan chemical co

19171-19-8(Pomalidomide)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved